Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kyle P. Chiang is active.

Publication


Featured researches published by Kyle P. Chiang.


Proceedings of the National Academy of Sciences of the United States of America | 2002

A missense mutation in human fatty acid amide hydrolase associated with problem drug use

Jack C. Sipe; Kyle P. Chiang; Alexandra L. Gerber; Ernest Beutler; Benjamin F. Cravatt

Problem drug use and dependence are neurobehavioral disorders of complex origin. Although environmental factors contribute to drug abuse and addiction, genetic factors also play a significant role estimated at 40–60% of the total risk. Nonetheless, the precise identities of human genes that confer vulnerability to problem drug use remain mostly unknown. Here, we describe a natural single nucleotide polymorphism in the human gene that encodes the principal endocannabinoid-inactivating enzyme, fatty acid amide hydrolase (FAAH), that in homozygous form is strongly associated with both street drug use and problem drug/alcohol use. This single nucleotide polymorphism results in a missense mutation (385C→A) that converts a conserved proline residue to threonine (Pro129→Thr), producing a FAAH variant that displays normal catalytic properties but an enhanced sensitivity to proteolytic degradation. Collectively, these results suggest that genetic mutations in FAAH may constitute important risk factors for problem drug use and support a potential link between functional abnormalities in the endogenous cannabinoid system and drug abuse and dependence.


Proceedings of the National Academy of Sciences of the United States of America | 2005

A brain detoxifying enzyme for organophosphorus nerve poisons

Daniel K. Nomura; Donmienne Leung; Kyle P. Chiang; Gary B. Quistad; Benjamin F. Cravatt; John E. Casida

Organophosphorus (OP) insecticides and chemical warfare agents act primarily by inhibiting acetylcholinesterase. There are many secondary targets for OP toxicants as observed for example with the major insecticide chlorpyrifos and its bioactivated metabolite chlorpyrifos oxon (CPO). Therefore, it was surprising that the predominant mouse brain protein labeled in vitro by [3H-ethyl]CPO (1 nM) (designated CPO-binding protein or CPO-BP) is not one of these known OP toxicant targets. CPO-BP is a 50-kDa membrane-bound serine hydrolase measured by derivatization with [3H]CPO and SDS/PAGE or filtration binding assay. It appears to undergo rapid diethylphosphorylation by [3H]CPO followed by either dephosphorylation and reactivation or aging on loss of an ethyl group. CPO and several other OP toxicants potently inhibit CPO-BP in vivo (i.p., 2 h) (50% inhibition at 2-25 mg/kg) and in vitro (50% inhibition at 8-68 nM). Using three chemical labeling reagents, i.e., [3H]CPO and the activity-based proteomic probes fluorophosphonate-biotin and fluorophosphonate-rhodamine, mouse brain CPO-BP is identified as serine hydrolase KIAA1363 of unknown function. Brains from KIAA1363-/- mice show greatly reduced levels of CPO labeling and hydrolytic metabolism compared to brains from wild-type mice. KIAA1363 therefore is the principal enzyme for metabolizing low levels of CPO in brain and may play a more general role in detoxification of OP nerve poisons.


Journal of Lipid Research | 2010

Cholesteryl ester hydrolase activity is abolished in HSL-/- macrophages but unchanged in macrophages lacking KIAA1363.

Marlene Buchebner; Thomas Pfeifer; Nora Rathke; Prakash G. Chandak; Achim Lass; Renate Schreiber; Adelheid Kratzer; Robert A. Zimmermann; Wolfgang Sattler; Harald Koefeler; Eleonore Fröhlich; Gerhard M. Kostner; Ruth Birner-Gruenberger; Kyle P. Chiang; Guenter Haemmerle; Rudolf Zechner; Sanja Levak-Frank; Benjamin F. Cravatt; Dagmar Kratky

Cholesteryl ester (CE) accumulation in macrophages represents a crucial event during foam cell formation, a hallmark of atherogenesis. Here we investigated the role of two previously described CE hydrolases, hormone-sensitive lipase (HSL) and KIAA1363, in macrophage CE hydrolysis. HSL and KIAA1363 exhibited marked differences in their abilities to hydrolyze CE, triacylglycerol (TG), diacylglycerol (DG), and 2-acetyl monoalkylglycerol ether (AcMAGE), a precursor for biosynthesis of platelet-activating factor (PAF). HSL efficiently cleaved all four substrates, whereas KIAA1363 hydrolyzed only AcMAGE. This contradicts previous studies suggesting that KIAA1363 is a neutral CE hydrolase. Macrophages of KIAA1363−/− and wild-type mice exhibited identical neutral CE hydrolase activity, which was almost abolished in tissues and macrophages of HSL−/− mice. Conversely, AcMAGE hydrolase activity was diminished in macrophages and some tissues of KIAA1363−/− but unchanged in HSL−/− mice. CE turnover was unaffected in macrophages lacking KIAA1363 and HSL, whereas cAMP-dependent cholesterol efflux was influenced by HSL but not by KIAA1363. Despite decreased CE hydrolase activities, HSL−/− macrophages exhibited CE accumulation similar to wild-type (WT) macrophages. We conclude that additional enzymes must exist that cooperate with HSL to regulate CE levels in macrophages. KIAA1363 affects AcMAGE hydrolase activity but is of minor importance as a direct CE hydrolase in macrophages.


Human Molecular Genetics | 2004

Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use

Kyle P. Chiang; Alexandra L. Gerber; Jack C. Sipe; Benjamin F. Cravatt


Angewandte Chemie | 2003

Benzoxazoles as Transthyretin Amyloid Fibril Inhibitors: Synthesis, Evaluation, and Mechanism of Action†

Hossein Razavi; Satheesh K. Palaninathan; Evan T. Powers; R. Luke Wiseman; Hans E. Purkey; Nilofar N. Mohamedmohaideen; Songpon Deechongkit; Kyle P. Chiang; Maria Dendle; James C. Sacchettini; Jeffery W. Kelly


Chemistry & Biology | 2006

An Enzyme that Regulates Ether Lipid Signaling Pathways in Cancer Annotated by Multidimensional Profiling

Kyle P. Chiang; Sherry Niessen; Alan Saghatelian; Benjamin F. Cravatt


Journal of Medicinal Chemistry | 2002

Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors.

Vibha Oza; Craig Smith; Prakash Raman; Edward K. Koepf; Hilal A. Lashuel; H. Mike Petrassi; Kyle P. Chiang; Evan T. Powers; James Sachettinni; Jeffery W. Kelly


Journal of Medicinal Chemistry | 2005

Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation

Steven M. Johnson; H. Michael Petrassi; Satheesh K. Palaninathan; Nilofar N. Mohamedmohaideen; Hans E. Purkey; Christopher J. Nichols; Kyle P. Chiang; Traci Walkup; James C. Sacchettini; K. Barry Sharpless; Jeffery W. Kelly


Journal of the American Chemical Society | 2005

Potent and Selective Structure-Based Dibenzofuran Inhibitors of Transthyretin Amyloidogenesis: Kinetic Stabilization of the Native State

H. Michael Petrassi; Steven M. Johnson; Hans E. Purkey; Kyle P. Chiang; Traci Walkup; Xin Jiang; Evan T. Powers; Jeffery W. Kelly


Bioorganic & Medicinal Chemistry Letters | 2005

Design, synthesis, and evaluation of oxazole transthyretin amyloidogenesis inhibitors.

Hossein Razavi; Evan T. Powers; Hans E. Purkey; Sara L. Adamski-Werner; Kyle P. Chiang; Maria Dendle; Jeffery W. Kelly

Collaboration


Dive into the Kyle P. Chiang's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jeffery W. Kelly

Scripps Research Institute

View shared research outputs
Top Co-Authors

Avatar

Evan T. Powers

Scripps Research Institute

View shared research outputs
Top Co-Authors

Avatar

Hans E. Purkey

Scripps Research Institute

View shared research outputs
Top Co-Authors

Avatar

Alan Saghatelian

Salk Institute for Biological Studies

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hossein Razavi

Scripps Research Institute

View shared research outputs
Researchain Logo
Decentralizing Knowledge